YU75800A - Terapeutske kombinacije koje sadrže modulator selektivnog estrogen receptora i paratiroidni hormon - Google Patents
Terapeutske kombinacije koje sadrže modulator selektivnog estrogen receptora i paratiroidni hormonInfo
- Publication number
- YU75800A YU75800A YU75800A YU75800A YU75800A YU 75800 A YU75800 A YU 75800A YU 75800 A YU75800 A YU 75800A YU 75800 A YU75800 A YU 75800A YU 75800 A YU75800 A YU 75800A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- parathyroid hormone
- compositions
- estrogen receptor
- receptor modulator
- selective estrogen
- Prior art date
Links
- 102000003982 Parathyroid hormone Human genes 0.000 title abstract 2
- 108090000445 Parathyroid hormone Proteins 0.000 title abstract 2
- 239000000199 parathyroid hormone Substances 0.000 title abstract 2
- 229960001319 parathyroid hormone Drugs 0.000 title abstract 2
- 229940095743 selective estrogen receptor modulator Drugs 0.000 title 1
- 239000000333 selective estrogen receptor modulator Substances 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 4
- 208000036119 Frailty Diseases 0.000 abstract 2
- 206010003549 asthenia Diseases 0.000 abstract 2
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 208000001164 Osteoporotic Fractures Diseases 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- GXESHMAMLJKROZ-IAPPQJPRSA-N lasofoxifene Chemical compound C1([C@@H]2[C@@H](C3=CC=C(C=C3CC2)O)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 GXESHMAMLJKROZ-IAPPQJPRSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Ovaj pronalazak se odnosi na farmaceutsku kombinaciju preparata i na postupke koji sadrže (-)-cis-6-fenil-5-(4-(2-pirolidin-1-il-etoksi)-fenil)-5,6,7,8-tetrahidronaftalen-2-ol ili njegovu farmaceutski prihvatljivu so i paratiroidni hormon ili njegov biološki aktivni fratgment, postupke korišćenja takvih preparata i kitove koji sadrže takve preparate. Preparati su korisni za tretiranje muskuloskeletne slabosti, uključujući osteroporozu, osteoporotni prelom, malu koštanu masu i slabost.[This invention is directed to pharmaceutical combination compositions and methods comprising (-)-cis-6-phenyl-5-(4-(2-pyrrolidin- 1-yl-ethoxy)-phenyl)-5,6,7,8-tetrahydronaphthalene-2-ol or a pharmaceutically acceptable salt thereof and parathyroid hormone or a biologically active fragment thereof, methods of using such compositions and kits containing such compositions. The compositions are useful for treating musculoskeletal frailty, including osteoporosis, osteoporotic fracture, low bone mass and frailty.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8947998P | 1998-06-16 | 1998-06-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| YU75800A true YU75800A (sh) | 2003-12-31 |
Family
ID=22217879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| YU75800A YU75800A (sh) | 1998-06-16 | 1999-05-26 | Terapeutske kombinacije koje sadrže modulator selektivnog estrogen receptora i paratiroidni hormon |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US6132774A (sh) |
| EP (1) | EP1094808A1 (sh) |
| JP (1) | JP2002518323A (sh) |
| KR (1) | KR20010052818A (sh) |
| CN (1) | CN1305373A (sh) |
| AP (1) | AP9901580A0 (sh) |
| AR (1) | AR018867A1 (sh) |
| AU (1) | AU3725999A (sh) |
| BG (1) | BG105125A (sh) |
| BR (1) | BR9911228A (sh) |
| CA (1) | CA2335078A1 (sh) |
| CO (1) | CO5070584A1 (sh) |
| EA (1) | EA200001199A1 (sh) |
| GT (1) | GT199900066A (sh) |
| HN (1) | HN1999000063A (sh) |
| HR (1) | HRP20000858A2 (sh) |
| HU (1) | HUP0102759A3 (sh) |
| ID (1) | ID26873A (sh) |
| IL (1) | IL139588A0 (sh) |
| IS (1) | IS5719A (sh) |
| MA (1) | MA26649A1 (sh) |
| NO (1) | NO20006313L (sh) |
| NZ (1) | NZ508039A (sh) |
| OA (1) | OA11566A (sh) |
| PA (1) | PA8471201A1 (sh) |
| PE (1) | PE20000644A1 (sh) |
| PL (1) | PL344982A1 (sh) |
| SK (1) | SK18922000A3 (sh) |
| TN (1) | TNSN99119A1 (sh) |
| TR (1) | TR200003567T2 (sh) |
| UA (1) | UA60367C2 (sh) |
| WO (1) | WO1999065482A1 (sh) |
| YU (1) | YU75800A (sh) |
| ZA (1) | ZA993972B (sh) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HN1996000101A (es) * | 1996-02-28 | 1997-06-26 | Inc Pfizer | Terapia combinada para la osteoporosis |
| US20020107230A1 (en) * | 2000-12-22 | 2002-08-08 | Waldon R. Forrest | Methods and formulations for the treatment of female sexual dysfunction |
| US20030191096A1 (en) * | 2002-04-03 | 2003-10-09 | Leonard Thomas W. | Method of hormonal therapy |
| EP1689383B1 (en) | 2003-11-19 | 2012-10-31 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing thyromimetics |
| WO2006056845A1 (en) * | 2004-11-23 | 2006-06-01 | Warner-Lambert Company Llc | 7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for the treatment of lipidemia |
| US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
| US7790745B2 (en) | 2005-10-21 | 2010-09-07 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline LXR Modulators |
| US7919506B2 (en) | 2006-03-10 | 2011-04-05 | Pfizer Inc. | Dibenzyl amine compounds and derivatives |
| US8404896B2 (en) | 2006-12-01 | 2013-03-26 | Bristol-Myers Squibb Company | N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases |
| WO2010093601A1 (en) | 2009-02-10 | 2010-08-19 | Metabasis Therapeutics, Inc. | Novel sulfonic acid-containing thyromimetics, and methods for their use |
| TW201043595A (en) * | 2009-03-13 | 2010-12-16 | Organon Nv | Tetrahydronaphthalen-2-ol derivatives |
| DE102010027016A1 (de) | 2010-07-09 | 2012-01-12 | Universitätsklinikum Jena | Steroid-Styrylfarbstoff-Konjugate zur Simulation und direkten lichtoptischen Detektion des Verhaltens von Steroiden im lebenden biologischen Gewebe und in Gegenwart von steroidbindenden Proteinen |
| CN111067907A (zh) * | 2018-10-18 | 2020-04-28 | 常州大学 | 孕激素在抑制血管内皮生长因子表达中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5254595A (en) * | 1988-12-23 | 1993-10-19 | Elf Sanofi | Aryloxypropanolaminotetralins, a process for their preparation and pharmaceutical compositions containing them |
| US5552412A (en) * | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
| TW432073B (en) * | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
| HN1996000101A (es) * | 1996-02-28 | 1997-06-26 | Inc Pfizer | Terapia combinada para la osteoporosis |
-
1999
- 1999-04-29 PA PA19998471201A patent/PA8471201A1/es unknown
- 1999-05-03 HN HN1999000063A patent/HN1999000063A/es unknown
- 1999-05-10 GT GT199900066A patent/GT199900066A/es unknown
- 1999-05-26 IL IL13958899A patent/IL139588A0/xx unknown
- 1999-05-26 TR TR2000/03567T patent/TR200003567T2/xx unknown
- 1999-05-26 EA EA200001199A patent/EA200001199A1/ru unknown
- 1999-05-26 PL PL99344982A patent/PL344982A1/xx unknown
- 1999-05-26 OA OA1200000340A patent/OA11566A/en unknown
- 1999-05-26 SK SK1892-2000A patent/SK18922000A3/sk unknown
- 1999-05-26 HU HU0102759A patent/HUP0102759A3/hu unknown
- 1999-05-26 US US09/424,010 patent/US6132774A/en not_active Expired - Fee Related
- 1999-05-26 BR BR9911228-0A patent/BR9911228A/pt not_active IP Right Cessation
- 1999-05-26 NZ NZ508039A patent/NZ508039A/xx unknown
- 1999-05-26 JP JP2000554362A patent/JP2002518323A/ja active Pending
- 1999-05-26 KR KR1020007014141A patent/KR20010052818A/ko not_active Application Discontinuation
- 1999-05-26 YU YU75800A patent/YU75800A/sh unknown
- 1999-05-26 ID IDW20002626A patent/ID26873A/id unknown
- 1999-05-26 AU AU37259/99A patent/AU3725999A/en not_active Abandoned
- 1999-05-26 WO PCT/IB1999/000949 patent/WO1999065482A1/en not_active Application Discontinuation
- 1999-05-26 UA UA2000127244A patent/UA60367C2/uk unknown
- 1999-05-26 CN CN99807345A patent/CN1305373A/zh active Pending
- 1999-05-26 CA CA002335078A patent/CA2335078A1/en not_active Abandoned
- 1999-05-26 EP EP99919491A patent/EP1094808A1/en not_active Withdrawn
- 1999-06-10 AP APAP/P/1999/001580A patent/AP9901580A0/en unknown
- 1999-06-14 PE PE1999000526A patent/PE20000644A1/es not_active Application Discontinuation
- 1999-06-15 AR ARP990102846A patent/AR018867A1/es not_active Application Discontinuation
- 1999-06-15 MA MA25623A patent/MA26649A1/fr unknown
- 1999-06-15 ZA ZA9903972A patent/ZA993972B/xx unknown
- 1999-06-15 TN TNTNSN99119A patent/TNSN99119A1/fr unknown
- 1999-06-16 CO CO99037623A patent/CO5070584A1/es unknown
-
2000
- 2000-11-21 IS IS5719A patent/IS5719A/is unknown
- 2000-12-12 NO NO20006313A patent/NO20006313L/no not_active Application Discontinuation
- 2000-12-14 HR HR20000858A patent/HRP20000858A2/hr not_active Application Discontinuation
-
2001
- 2001-01-08 BG BG105125A patent/BG105125A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| YU18400A (sh) | Prostaglanidin agonisti i njihova primena za tretiranje koštanih poremećaja | |
| YU75800A (sh) | Terapeutske kombinacije koje sadrže modulator selektivnog estrogen receptora i paratiroidni hormon | |
| AP9801269A0 (en) | Prostaglandin agonists. | |
| NO20040331L (no) | Legemidler for sykdommer med benmassetap som har Eragonist som den aktive bestanddel | |
| IL180603A (en) | 3,4-Dihydro-1 H- Naphthalanones which are glucocorticoid receptor modulators | |
| YU7797A (sh) | Kombinovana terapija za osteoporozu | |
| BR9804437A (pt) | Compostos para a osteoporose | |
| HUP0102913A3 (en) | Use of biogenic estrogen sulfamates for producing pharmaceutical compositions for hormone replacement therapy | |
| NZ531018A (en) | 5-CNAC as oral delivery agent for parathyroid hormone fragments | |
| SI1079803T1 (en) | Protein formulations | |
| NO20006381L (no) | Terapeutiske kombinasjoner av (selektive) östrogenreseptormodulatorer (SERM) og veksthormonsekresjonsmidler | |
| EA200001186A1 (ru) | Терапевтические комбинации (избирательных) модуляторов рецепторов эстрогенов (имрэ) и стимуляторов секреции гормона роста (ссгр) для лечения скелетно-мышечной слабости | |
| CA2274381A1 (en) | Therapeutic combinations comprising a selective estrogen receptor modulator and prostaglandin e2 | |
| ECSP993016A (es) | Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratoroidea | |
| GB9823515D0 (en) | Agent for the treatment of osteoporosis | |
| UA28851A (uk) | Спосіб оперативного лікування переломів дистального метаепіфізу великогомілкової кістки | |
| TH57984A3 (th) | การรวมในทางการรักษาซี่งประกอบด้วยตัวปรับตัวรับเอสโตรเจนแบบคัดเลือกและฮอร์โมนพาราไธรอยด์ |